Clinical Trial Update: A Phase 1, SAD Study to Evaluate the Safety and Tolerability of LY03017 [Phase 1]

View source ↗

Summary

Phase 1 single-ascending-dose study to evaluate the safety and tolerability of LY03017; the trial is not yet recruiting for indications including Alzheimer's di…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Parkinson Disease
• Schizophrenia

Drugs mentioned

• LY03017

Snippet

Sponsor: Luye Pharma Group Ltd. | Conditions: Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis, Hallucinations and Delusions Associated With Parkinson Disease Psychosis | Phase 1 | Status: NOT_YET_RECRUITING